HBAN Medtech Syndicate
VC Fund
HBAN Medtech Syndicate is a VC fund focused on Medical Device and Medical. HBAN Medtech Syndicate
- Total investments:
- 13
- Last investment:
- Lead investor:
- 15%
Last updated:
For AI agents: llms.txt
Industries HBAN Medtech Syndicate invests in
Stages HBAN Medtech Syndicate invests in
Countries HBAN Medtech Syndicate invests in
Round sizes
Round size
- Seed
- $1.3M–$11M
Investment Focus
Industry
- Medical Device 6 (46%)
- Medical 5 (38%)
- Health Care 4 (31%)
- Hospital 1 (8%)
- Biotechnology 1 (8%)
Stage
- Seed 5 (38%)
- Funding Round 4 (31%)
- Series B 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| NeuroBell are developing a novel medical device providing portable EEG monitoring with real-time &automated neonatal seizure alerts at the bedside. | $5.5M / Jun 29, 2026 | ||
| NeuroBell are developing a novel medical device providing portable EEG monitoring with real-time &automated neonatal seizure alerts at the bedside. | $2.1M / Seed / Jan 08, 2024 | ||
| SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes significant shortness of breath and chest pain in up to 15% of patients with cancer. | $1.7M / Seed / Dec 21, 2023 | ||
| FeelTect’s technology, Tight Alright, is a pressure sensing, connected-health device for measuring and monitoring sub-bandage pressure during compression therapy, primarily for the millions of people worldwide with venous leg ulcers (VLUs). Compression is a proven therapy for VLUs, however if it’s applied too loose, it’s ineffective, and if it’stoo tight, it’s dangerous. | $1.6M / Dec 20, 2023 | ||
| FeelTect’s technology, Tight Alright, is a pressure sensing, connected-health device for measuring and monitoring sub-bandage pressure during compression therapy, primarily for the millions of people worldwide with venous leg ulcers (VLUs). Compression is a proven therapy for VLUs, however if it’s applied too loose, it’s ineffective, and if it’stoo tight, it’s dangerous. | $1.6M / Seed / Dec 20, 2023 | ||
| X-BOLT Orthopaedics developed a novel expanding bolt device, with associated implants and instrumentation systems, for internal bone fixation in osteoporotic hip fractures. X-BOLT hip plating and nailing systems allow surgeons choice to treat all morphologies of proximal femoral fractures. | $3.5M / Venture - Series Unknown / Oct 29, 2023 | ||
| It has been estimated that up to 25% of diabetics will develop a foot ulcer at some point in their life. One of the main causes is peripheral neuropathy, which results in a patient losing sensation in their feet. Of the millions who develop ulcers every year, hundreds of thousands will require amputation due to infection. In 2014, Ireland recordedan increase in the number of amputations as a result of diabetes, with 8 limbs being lost every week. | $11.5M / Mar 31, 2023 | ||
| It has been estimated that up to 25% of diabetics will develop a foot ulcer at some point in their life. One of the main causes is peripheral neuropathy, which results in a patient losing sensation in their feet. Of the millions who develop ulcers every year, hundreds of thousands will require amputation due to infection. In 2014, Ireland recordedan increase in the number of amputations as a result of diabetes, with 8 limbs being lost every week. | $11.4M / Seed / Mar 31, 2023 | ||
| Founded in 2014 by Eoin Bambury and Moshe Zilversmit, Signum Surgical is a medtech platform striving to develop technology that could cure perianal fistula. Bambury and Zilversmit, who met on the BioInnovate Ireland programme at NUI Galway, recognised a lack of innovation surrounding the treatment of perianal fistulas (small tunnels that developbetween the end of the bowel and the skin near the anus). The device developed by Signum Surgical is implanted post-surgery to prevent reinfection and to allow a faster healing process. | $2.9M / Venture - Series Unknown / Sep 20, 2022 | ||
| Founded in 2017, Deciphex aims to transform diagnostic workflows through AI-powered digital pathology to improve patient outcomes worldwide. Its two flagship platforms target distinct markets: Diagnexia connects global subspecialty pathologists for rapid diagnostics and backlog reduction, while Patholytix accelerates drug development throughoptimized preclinical safety assessments. By automating routine tasks, these platforms enable pathologists to focus on complex cases while delivering faster, more reliable diagnoses. Through this combination of AI innovation and clinical expertise, Deciphex is advancing both healthcare delivery and therapeutic development. | $11.5M / Series B / May 19, 2022 | ||
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does HBAN Medtech Syndicate invest in?
HBAN Medtech Syndicate invests primarily in Medical Device, Medical and Health Care startups, most often at Seed and Funding Round stage. Most of the 13 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is HBAN Medtech Syndicate's check size?
HBAN Medtech Syndicate typically joins rounds of $1.3M–$11M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds HBAN Medtech Syndicate participates in.
When did HBAN Medtech Syndicate last invest?
The most recent investment recorded for HBAN Medtech Syndicate closed in Jun 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
